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1. Introduction  
The prescription of drugs is an instrumental practice of modern therapeutics. According to 
the definition of the World Health Organization, the adequate prescription involves the 
selection of the correct drug, dose and duration of administration. In this sense, it is known 
that drugs that are prescribed for certain indications cannot produce the desired therapeutic 
effect in approximately 30 to 60% of the cases (Wang et al., 2011). 
The pharmacological effects of most drugs depend on the result of a series of 
pharmacokinetic processes, which determine the amount of drug that reaches the 
biophase (target tissues), as well as on pharmacodynamics, involving the interaction 
between the drug and its site of action. These processes occur at variable levels in 
different individuals, and one of the major determinants of this variability is genetics. The 
structure, function and expression of most enzymes involved in drug transport and 
metabolism as well as the specific drug receptors may be affected by the presence of 
genetic variants, which may in turn modify the intended therapeutic effect or the 
appearance of adverse effects. In cases in which polymorphisms or mutations affect the 
structure or expression of these proteins, with corresponding implications in their 
function, genomic analyses can be applied to predict the patient’s response prior to 
treatment. This concept represents the central aim of pharmacogenomics (Weinshilboum 
& Wang, 2006). 
Importantly, pharmacogenomic analyses do not explain all of the variability in drug 
responses. The new paradigm of individualized therapy must combine genetic 
information and non-genetic factors, such as sex, age, diet, environmental factors, drug 
interactions, demographics and clinical observations to determine the best treatment for a 
patient, both in the selection of drugs and in the dosage; the aim is to optimize the 
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patient’s therapeutic experience (Belloso & Redal, 2010). As with other areas of modern 
therapeutics, pharmacogenomics is gaining a place in the treatment of gastroenterological 
diseases.  
Some gastroenterological diseases, such as gastroesophageal reflux and peptic ulcer disease, 
are among the most frequent and relevant pathologies in adult patients. In addition, 
inflammatory bowel disease, hepatitis C and postoperative or cancer-associated nausea and 
vomiting are conditions in which pharmacological therapy does not show a universal 
response. Interestingly, genetic factors may partially explain this variability of therapeutic 
efficacy for most drugs that are used in the treatment of these important gastroenterologic 
disorders. 
In this chapter, we evaluate the major polymorphisms that are associated with the 
effectiveness or toxicity of drugs that are commonly used in gastroenterology. 
2. Genes and polymorphisms 
The magnitude of the expression of transporters, metabolizing enzymes and receptors 
depend primarily on genetic factors. Among these factors, different types of inherited 
genetic variants may be found, such as deletions, insertions and the multiplication or 
repetition of sequences, which may involve large portions of DNA. However, the most 
frequent variants and the most common targets of pharmacogenetic tests are the single 
nucleotide polymorphisms (SNPs). SNPs are modifications of a single base in the nucleotide 
sequence.  
Studies of the human genome sequence have established that there are more than 15 
million SNPs, of which only a small minority appear to have any impact on the kinetics or 
dynamics of drugs. Different approaches of pharmacogenomic study can range from 
purely genetic to the identification of those SNPs that confer clinical impacts; conversely, 
they can include the identification of specific sequences of nucleotides to recognize 
individuals with particular behaviors in relation to metabolism or drug responses (The 
International HapMap Consortium: A haplotype map of the human genome, 2005; Redon et al., 
2006). 
The genes that encode metabolic proteins, transporters or receptors may have different 
polymorphisms, and some of these polymorphisms will confer a particular impact on the 
magnitude of the expression of the gene products (Leucuta & Viase, 2006). 
A polymorphism is considered when an allelic variant appears in more than 1% of the 
general population. These variants may be associated with a deficient expression or, in a 
minority of the cases, the overexpression of the enzyme, transporter or receptor. 
For most drugs, the genotypic study of its metabolizing enzymes does not exhaust the 
potential sources of genetic variability. By accounting for the overall potential 
polymorphisms of transporters and receptors that are involved in the pharmacology of 
drugs, it may be possible to characterize multiple SNPs from multiple genes, which would 
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3. Peptic ulcer disease by Helicobacter pylori infection and gastro 
esophageal reflux disease 
3.1 Clinical characteristics 
Helicobacter pylori (HP) infection is associated with chronic gastritis, peptic ulcer disease, 
gastric mucosal associated lymphoid tissue (MALT) lymphoma and gastric cancer. The 
eradication of bacterial infection provides an effective means of curing or preventing these 
HP-associated diseases.  
Gastroesophageal reflux disease (GERD) is noted by its prevalence, variety of clinical 
presentations and under-recognized morbidity. In general, GERD is considered for patients 
who demonstrate symptoms that are suggestive of reflux or complications thereof and with 
or without esophageal inflammation. 
The most common symptoms of GERD are heartburn (or pyrosis), regurgitation and 
dysphagia. In addition, a variety of extraesophageal manifestations have been described 
including bronchospasm, laryngitis, and chronic cough. 
A possible role for HP in the pathogenesis of GERD has also been suggested. However, the 
link between GERD and HP is complex and remains poorly defined. 
3.2 Pharmacological treatment 
The current treatment strategies for the cure of HP infection are based on a triple therapy that 
includes a proton pump inhibitor (PPI) and two antibiotics, which are usually amoxicillin 
and/or clarithromycin or metronidazole. These regimens are effective in 70-90% of patients. 
Treatment failures have been attributed to bacterial resistance to the antibiotics.  
PPIs also constitute the standard treatment for GERD; in fact, the introduction of PPIs for 
the management of acid-peptic disorders constitutes one of the great success stories in 
gastroenterology because of their efficacy and safety. Nevertheless, the treatment response 
is not uniform, and in fact, the average response to treatment may actually hamper the 
identification of two different populations of patients, which include those who respond 
almost completely and those who have a consistently suboptimal response. 
3.3 Pharmacogenomic considerations 
Among the mechanisms of drug metabolism in the body, the most important is cytochrome 
P450. The complex enzymes that are involved in the metabolism of drugs include CYP2C19, 
CYP2D6, CYP2C9 and CYP3A4/5/7. 
The CYP2C19 isoenzyme metabolizes all of the PPIs that are currently available, some 
antidepressant drugs, the antifungal voriconazole, thalidomide and the antiplatelet 
clopidogrel.  
The gene that encodes CYP2C19 has been mapped to chromosome 10 (10q24.1-q24.3). At 
least 21 variants of CYP2C19, from *1 to *20, have been identified. CYP2C19*1 is the wild-
type allele. The variant allele CYP2C19*2, which contains 681G>A on exon 5 that causes a 
splicing defect, which is the major genetic defect that is responsible for the polymorphism of 
S-mephenytoin metabolism in humans. CYP2C19*3 carries the 636G>A SNP, which results 
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in a premature stop codon in exon 4. Both CYP2C19*2 and *3 are null alleles, which result in 
the absence of enzymatic activity (de Morais et al., 1994). The majority of the PMs of 
CYP2C19 are due to these two variant alleles (Desta et al., 2002). 
It has been described that approximately 3-5% of the Caucasian population has a total 
absence of enzymatic activity that is primarily associated with the gene variant CYP2C19*2, 
and it is associated to a lesser extent with CYP2C19*3. The frequency of these 
polymorphisms is highly variable among different populations (Goldstein et al., 1997). 
Likewise, the CYP2C19 * 17 variant (I331V) was identified more recently, and it is found in 
ultra-rapid metabolizers (UMs) (Sim, 2006). The alleles *2 and *3, which are associated with 
poor metabolizers (PMs), have been found in approximately 85% of the Caucasian 
population and nearly 100% of the Asian population. If the alleles *4 and *6 are included, the 
prevalence of the PM phenotype in Caucasians is 92%. 
The biotransformation of PPI occurs primarily through CYP2C19, and the study of 
polymorphisms for these drugs has a specific application. CYP2C19 is responsible for the 
initial hydroxylation of omeprazole and lanzoprazole and, to a lesser extent, the 
demethylation of pantoprazole and rabeprazole, which are the steps that produce 
metabolites without antacid activity (figure 1). The ability of these drugs to reduce gastric 
acidity depends largely on the concentration that is reached in the plasma after absorption. 
Therefore, those who rapidly metabolize the drugs ,rapid metabolizers (RMs) have 
significantly lower gastric pH values than those who are “extensive metabolizers”, 
“intermediate metabolizers” (IMs) or PMs. The PMs have inherited variations in both of the 
alleles and therefore cannot express the functional enzyme. The differences in the area 
under the curve (AUC), which is a variable that quantifies the exposure of the subject to the 
current drug, can be up to 13-fold higher for the PM in the case of omeprazole. 
In addition, it has been observed that these pharmacokinetic and pharmacodynamic 
differences result in diverse clinical outcomes by using proton- pump inhibitor therapies, 
which are primarily used in the treatment of gastroesophagic reflux disease (GERD) and the 
eradication of HP (Furuta, 2005).  
 
Fig. 1. Metabolism of omeprazole, lanzoprazole and rabeprazole 
3.4 Pharmacogenomic influences in the treatment of GERD with PPIs  
In recent years, it has been established that one of the causes of GERD that is refractory to 
PPI therapy, which occurs in approximately 10% of patients, is related to differences in the 
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efficiency of the metabolism of the drug. Endoscopic cure rates are much lower in RMs than 
in IMs, and higher cure rates are observed in the PMs, which display a poorer outcome in 
relation to the severity of the injury (less than 17% for RM C or D lesions, Los Angeles 
classification). It was established that the genotype is also crucial for the nocturnal acid 
bouts, which are episodes in which the pH falls below 4 for more than an hour and are 
considered to be an influential factor in the treatment outcome. These intrusions are much 
more frequent in RMs than in the other two types of metabolizing patterns. This result 
suggests that patients who are refractory to standard doses of PPI should be offered an 
increased dose or frequency on the premise that they are RMs (Kawamura et al., 2007; Egan 
et al., 2003). 
The safety profile of PPIs also seems to be influenced by pharmacogenetics, which is 
illustrated in the case of GERD treatments that require long treatment periods. There is 
some evidence that IMs and, to a larger extent, PMs, have a higher risk of hyperplasia of 
enterochromaffin-like cells, which is related to the development of carcinoid tumors, than 
their RM counterparts (Rosemary & Adithan, 2007). Likewise, the first two groups have 
higher rates of megaloblastic anemia by vitamin B12 deficiency, which arises from the 
neutralization of the gastric pH for extended periods; these groups also suffer from atrophic 
gastritis, which is especially likely if it coexists with HP infection (Kang, 2008).  
3.5 Pharmacogenomic influences on the eradication of Helicobacter pylori  
To eradicate and as a part of the therapeutic strategy for managing patients with various 
conditions, such as peptic ulcer disease or MALT, PPIs are a central part of the scheme 
that also require the addition of antibiotics. The suppression of gastric acidity is also 
crucial for the bioavailability and stabilization of the plasma concentration of antibiotics, 
which can force HP to its growth phase, which is where it is most responsive to treatment, 
increase the intragastric concentrations of antibiotics and provide some intrinsic actions 
against HP. 
Response rates in the eradication of HP are also influenced by the genotype of the patient 
(figure 2), such that the PMs are able to achieve 100% eradication with the standard dose of 
PPIs and with the addition of 500 mg of amoxicillin and omeprazole four times a day for 
two weeks. In this scheme, the eradication rate for IMs is 60%, and that for RMs is only 30% 
(Kang, 2008). In addition, adequate results have been reported with dual schemes that 
utilize 10 mg of rabeprazole twice per day, which has a greater ability to suppress gastric 
acidity than omeprazole that is combined with amoxicillin, and has reached 90% eradication 
in both PMs and IMs (Furuta, 2005). Therefore, in a large number of cases, the use of a 
second antibiotic may be avoided. Moreover, in the cases of eradication failure, an attempt 
can be made by doubling the dose of rabeprazole with amoxicillin before a third antibiotic is 
added; the intention of this treatment is to achieve effectiveness in the case of RMs. This 
differential approach that permits the individualization of PPI treatment according to the 
CYP2C19 genotype constitutes a real breakthrough, and it facilitates the avoidance of the 
addition of clarithromycin or metronidazole, which are not exempt from adherence 
problems, cost, resistance and adverse effects. 
The addition of clarithromycin to the regimen of PPIs and amoxicillin has a pharmacokinetic 
basis: clarithromycin inhibits another cytochrome, CYP3A4, which is an alternative pathway 
for the metabolism of PPIs. Therefore, PPI concentrations are extremely high when PMs are 
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exposed concomitantly to these drugs and clarithromycin, although the rise of the plasma 
concentration has been observed with all of the genotypes (Furuta, 1999).  
This technique may represent one mechanism to increase the effectiveness of the triple 
scheme regardless of the CYP2C19 genotype. Nevertheless, the RMs cure rates are lower 
than the IMs and PMs cure rates, which is probably because the RMs receive insufficient 
doses of PPIs in accordance with the enzyme expression. It is believed that in the case of the 
triple scheme, prior knowledge of CYP2C19 genotype may help to optimize the dose of PPI 
to minimize the possibility of therapeutic failures. It is recommended that the dose and the 
dosing interval, up to four times daily, should be increased to ensure a gastric pH that is 
close to 7 for the majority of the day (Chaudhry & Kochhar, 2008). 
Finally, in patients for whom therapy has been individualized but fails to eradicate the 
disease, a consideration should be made regarding the possibility of an infection by a HP 













Fig. 2. Omeprazole metabolism by CYP2C19. (Furuta et al, 1998) 
The percent of HP eradication is dependent upon the metabolizer phenotype. 
4. Inflammatory Bowel Disease 
4.1 Clinical characteristics 
Inflammatory bowel disease (IBD) is a chronic, disabling disease that generally presents 
with flares and remissions. Ulcerative colitis (UC) and Crohn's disease constitute the most 
frequent forms of presentation.There are remarkable differences between both conditions 
regarding the clinical presentation, extension and extra-intestinal manifestations of the 
disease. The precise etiology of IBD is unknown, but both ambient and genetic factors may 
play a significant role. 
4.2 Pharmacological treatment 
The clinical course of this condition has changed substantially since immune modulator 
therapies and monoclonal antibodies were introduced to the therapeutic armamentarium; as 
a result, the extent of the remission periods has increased. However, a curative 
pharmacological approach is not yet available.  
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In addition, considerable variability exists regarding the efficacy and toxicity of the 
treatment. Multiple factors may influence the response to treatment, which include disease 
severity and complications; environmental factors, such as smoking; and genetic factors. It is 
estimated that between 20% and 95% of the variability in the toxicity and the treatment 
response may be explained by polymorphisms. The overall response rate to the treatment is 
more difficult to estimate than toxicity because there are multiple confounding factors, such 
as the concomitant use of other drugs, which may influence outcomes. The polymorphism 
of the enzyme thiopurine methyl transferase (TPMT) (figure 3) and its influence on 
treatment with Azathioprine (AZA) and 6-mercaptopurine (6-MP) is the best example of 
how genotyping can help to optimize therapy in inflammatory bowel disease (Hindorf et al., 
2002), (table 1). 
 
Fig. 3. Allelic variant of the TMPT locus. The boxes depict exons in the TMPT gene. The grey 
boxes are the untranslated region and blue boxes represent exons in the open reading frame. 
The green boxes are exons that contain mutations resulting in amino acid changes. 
 
Genotype Phenotype / Activity AZA dose 
TMPT*1/*1 High Standard doses 
TMPT*1/*2 
TMPT*1/*3 (A,B or C) 
Intermediate Half dose 
TMPT*2/*3 (A,B or C) 





Table 1. Relationship between genotype and phenotype in TPMT and doses of AZA in 
patients with IBD 
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AZA is a thiopurine derivative with immunosuppressive properties that has been 
available on the market for almost 40 years. It is widely used in the treatment of 
rheumatic diseases of children and adults, transplantation and inflammatory bowel 
disease, and it is used in different treatment combinations. However, approximately 40% 
of IBD patients do not respond to AZA treatment, and 10-25% must discontinue treatment 
because of adverse reactions, being either major (leukopenia, pancreatitis and hepatitis) or 
minor (rash, nausea, flu-like syndrome and diarrhea) Adverse reactions, which include 
liver, gastrointestinal and bone marrow toxicity are present in approximately 15-28% of 
patients.  
Hematologic toxicity occurs in approximately 2-9% of patients, and it can, in extreme cases, 
lead to death (Pierik et al., 2006).  
AZA is a pro-drug that is administered orally in doses of approximately 2.5 mg/kg per day. 
Fifteen to sixty percent of the drug is absorbed in the intestine, and after it enters the body, it 
is converted to 6-MP by a non-enzymatic reaction. 6-MP is also a pro-drug that undergoes a 
series of enzymatic reactions to form thioguanide nucleotides (6-TGNs), which are active 
metabolites that antagonize the metabolism of purines; inhibit the synthesis of DNA, RNA 
and proteins; and may also interfere with cellular metabolism and prevent mitosis. 6-TGNs 
are responsible for the immunosuppressive activity and the myelosuppressive action of 
AZA. 
The inactivation of AZA and 6-MP depend primarily on two metabolic pathways; one 
pathway utilizes xanthine oxidase, producing 6-thiouric acid, and the other utilizes TPMT, 
which converts the original drug to 6-methylmercaptopurine. Both of the metabolites are 
inactive.  
In myelopoietic precursors, no xanthine oxidase activity is observed; therefore, TPMT 
expression and function are vital for the inactivation of thiopuric derivatives.  
However, the accumulation of active metabolites also depends on the activity of these 
enzymes. In this regard, the toxicity of both AZA and 6-MP are strongly related to the TMPT 
activity. The decreased activity or deficiency of TMPT causes 6-MP to be preferentially 
metabolized to 6-TGNs, which are responsible for much of the toxicity of 6-MP. 
Following the introduction of the pharmacogenetic test for TPMT, there have been major 
changes in the prescription patterns of AZA in the last decade. The choice to use or not use 
AZA in accordance with the TPMT genotype offers the possibility of a safer and more 
effective treatment. 
Several studies have shown that 80-90% of patients who have at least one of the 
aforementioned variants will have to discontinue AZA treatment due to adverse effects, 
which primarily include neutropenia (Evans & McLeod, 2003). 
4.3 Pharmagenomic considerations 
Supporting evidence currently exists for the pre-treatment genetic testing of TPMT in the 
reduction of neutropenic episodes in patients receiving azathioprine, although the evidence 
regarding its contribution in increasing drug efficacy is not as strong (Lakatos, 2010). A 
recent survey in the UK showed that 67% of gastroenterologists used TPMT testing before 
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prescribing AZA (Payne et al., 2007). In 2004, the US Food and Drug Administration (FDA) 
approved TPMT testing in the US and made the recommendation to include this 
information in the drug prescription brochure; however, no formal recommendation was 
made for mandatory testing. 
A socio-economic study of IBD has demonstrated that TPMT genotyping is a cost-effective 
method that can identify patients with active low/absent enzyme to avoid treatment with 
AZA and its subsequent severe hematologic complications (van den Akker, 2006) 
It is now recommended that patients with IBD who have low or intermediate enzyme 
activity should receive a starting dose of 50% of the usually prescribed does, and treatment 
with AZA should be avoided in patients with null enzymatic activity to prevent toxicity 
(Pierik et al., 2006; Lakatos, 2010) 
5. Gilbert Meulengracht syndrome and irinotecan 
5.1 Clinical characteristics 
Gilbert syndrome is characterized by the presence of unconjugated hyperbilirubinemia, 
which is usually moderate, transient or intermittent; has a non-obstructive origin without 
liver inflammation or fibrosis; and is not associated with changes in histology. 
The occurrence of this syndrome is primarily related to the genetic variability in a family of 
enzymes (UDP-glucuronyltranferase (UGTs)) that are part of a detoxification system against 
endogenous toxins and xenobiotic chemicals. These membrane enzymes catalyze the 
glucuronidation of different substances by making them more polar to facilitate their 
excretion through bile or urine.  
This is a route of detoxification that is used for substances that are taken with meals, tobacco 
smoke, or drugs; however, this route is primarily involved in the maintenance of the 
homeostasis of endogenous substances, such as bilirubin, steroids, thyroid hormones and 
bile acids (Strassbourg, 2008).  
5.2 Pharmacogenomic considerations 
Different polymorphisms are associated with the variable activity of these enzymes, 
which affects their ability to detoxify substances. Subsequently, the glucuronidated 
products are recognized by transport systems for organic anions, and they are secreted in 
urine or bile.  
From a pharmacogenetic standpoint, the primary current use of the identification of alleles 
of UGT1A1 is focused on the ability to adequately predict the occurrence of severe 
hematologic toxicity (grade 3 or 4) in cytostatic treatment combinations, which include high 
doses of irinotecan. 
The UGT1A1 enzyme is the only enzyme that is relevant in the metabolism of bilirubin. 
At least 113 variants have been identified, but very few are common in the general 
population. One hundred ninety-five SNPs have been identified in the UGT1A1 gene. 
Among these, there are 11 SNPs in exons 1-5. The UGT1A1*6 (211 G>A) in exon 1 is the 
most common SNPs that is found in the East Asian population (15.7%), but it is not 
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common in the Caucasian population (0.7%) (Bernabeu et al., 2010). It has been suggested 
that the allele *6 contributes to the high incidence of neonatal hyperbilirubinemia in Asian 
children (Akaba et al., 1999). Exon 1 is unique for each member of the UGT1A1 subfamily, 
whereas exons 2 to 5 are common to all of the members of the subfamily. The variants in 
the 3´UTR of UGT1A1 in exon 5, therefore, may have distinct effects on all of the members 
of the UGT1A1 subfamily.  
Polymorphism in the promoter region of the UGT1A1 gene is caused by variability in the 
number of TA repeats in the TATA-box that is located upstream of UGT1A1. The presence 
of seven TA repeats (UGT1A1*28) is associated with reduced UGT1A1 expression 
compared to the wild type allele (UGT1A1*1), which contains six TA repeats. 
Homozygous individuals who carry the A (TA)7 TAA allele show significantly higher 
plasma levels of unconjugated bilirubin caused by a 30% reduction in the transcription of 
UGT1A1 (Lyer et al., 2002). There are interethnic differences in the frequency of the 
UGT1A1*28 allele, which has an approximate incidence of 6-12% in the Caucasian 
population, 0-3% in the Asian population and 16-19% in the African population (Shu-Feng 
Zhou et al., 2008). 
However, there are other polymorphisms, such as UGT1A1*36, which contains 5 TA; 
UGT1A1*37, which contains 8 TA; and other polymorphisms that are not linked to the 
TATA-box region, such as the variant UGT1A1*7 (1456T>G, mutation in exon 1); 
UGT1A1*27 (686C>A), which is very rare in all of the ethnic groups that were examined; 
and the variant UGT1A1*62, which is found exclusively in Asians and is not present in 
either Caucasians or Africans.  
Because haplotypes with UGT1A1 variants may coexist in the same person, the scenario is 
actually more complex. This may help to explain why there is hyperbilirubinemia in 5-9% 
of Caucasians, while 10-16% are homozygous for the UGT1A1*28 variant (Strassburg, 
2010).  
Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the 
enzyme topoisomerase I, which relieves DNA torsional strain by inducing reversible single-
strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA 
complex and prevent the relegation of these single-strand breaks. Current research suggests 
that the cytotoxicity of irinotecan is related to double-strand DNA damage that is produced 
during DNA synthesis, when replication enzymes interact with the ternary complex that is 
formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot 
efficiently repair these double-strand breaks. The irinotecan metabolite SN-38 is conjugated 
by UGT1A1. The presence of seven TA repeats, rather than the wild type number of six, in 
the UGT1A1 promoter reduces enzyme expression and consequently the expression of SN-
38; this also confers a higher chance of developing diarrhea and/or leukopenia during 
irinotecan therapy when compared to patients with a wild type genotype. Gilbert´s 
syndrome is also associated with the TA7/TA7 genotype, and these patients may have an 
increased risk of irinotecan-induced toxicity (Côté et al., 2007).  
In the same way, the recognition of patients with UGT1A1 deficiency may contribute to the 
prediction of the development of severe hyperbilirubinemia in patients with HIV infection 
who are treated with atazanavir, which is an enzyme blocker, and increased plasma 
concentrations of the integrase inhibitor raltegravir. 
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Irinotecam is primarily converted to its active metabolite SN-38 by liver carboxylesterases. 
UGT 1A1 inactivates SN-38 into the more polar SN-38 glucuronide, which is further 
eliminated in bile and urine (figure 4).  
 
 
Fig. 4. Metabolic pathway of irinotecan 
6. Hepatitis C infection 
6.1 Clinical characteristics 
The hepatitis C virus (HCV) infection affects over 170 million people worldwide; it causes 
chronic hepatitis, which may, in turn, lead to cirrhosis and hepatocellular carcinoma (HCC). 
There are six different genotypes whose prevalence varies geographically. Genotype I is 
responsible for most of the infections in North America, South America and Europe. Direct 
contact with blood (as in uncontrolled transfusions) or the use of parenteral drugs constitute 
the most common method of transmission, while unprotected sex is a secondary risk factor. 
A patient´s immune response will determine whether HCV is eventually eliminated or 
remains, which can produce a persistent infection; this latter outcome occurs in the majority 
of cases. The course of HCV infection is variable, although in most patients, it will progress 
toward cirrhosis.  
The hepatitis C virus is a flavivirus. The HCV genome is a positive-sense RNA molecule of 
approximately 9500 nucleotides and encodes a polyprotein precursor of approximately 3000 
amino acids. 
The observation of nucleotide and amino acid mutations that are specifically segregated in 
groups or subgroups in almost all of the regions of the HCV genome has permitted the 
classification of HCV genotypes and subtypes whose sequences differ from each other by 
30% and 20%, respectively. Currently, we accept the existence of at least 6 genotypes that are 
divided, in turn, into more than 84 subtypes. These genotypes were identified by a number 
(1 through 6), and the subtypes were identified by a lowercase letter in the order of their 
discovery (e.g., 1a, 1b, 2a, 3a, etc.). 
After they bind to the cell surface, HCV particles enter the cell by receptor-mediated 
endocytosis. The cytosolic recognition of specific motifs in viral products induces the 
production of interferons and proinflammatory cytokines, which leads to the recruitment of 
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a signaling complex that activates transcription factors. The subsequent expression of 
interferon alpha regulatory factor 3 (IRF-3) target genes, and likely lambda (type III) 
interferons induces innate immune programs and drives the maturation of adaptive 
immunity for infection control. The coordinated activities of CD4+ T cells and cytotoxic 
CD8+ T cells, which are primed in the context of HLA class II and I alleles, respectively, on 
antigen presenting cells, are critically important for the control of acute HCV infection. 
Mutations in viral epitopes that are targeted by cytotoxic CD8+ T cells can permit the virus 
to escape immunomediated clearance. The up-regulation of inhibitory receptors on 
exhausted (functionally impaired) T cells is another mechanism of T-cell dysfunction during 
chronic infection. 
The host immune response determines whether the HCV persists or is eradicated 
spontaneously.  
One of the most influential factors appears to be related to certain polymorphisms of a site 
that is in close proximity to the IL28B gene (Thomas et al., 2009; Grebely et al., 2010).  
The risk of chronic infection that follows an acute episode of hepatitis C is high. In most 
studies, 80% to hundred percent of patients remain HCV RNA-positive, and 60 to 80 percent 
have persistently elevated liver enzymes (Chu et al., 1999; Farci et al., 1991). The mechanism 
that is responsible for the high prevalence of chronic infection is unclear. This mechanism 
may be related to the genetic diversity of the virus and its tendency toward rapid mutation, 
which allows HCV to constantly escape immune recognition. Most patients with chronic 
infection are asymptomatic or have only mild, nonspecific symptoms. The most frequent 
complaint is fatigue; other less common manifestations include nausea, anorexia, myalgia, 
arthralgia, weakness, and weight loss.  
Cirrhosis occurs in up to 50 percent of chronically infected patients (Tong et al., 1995; 
Takahashi et al., 1993; Yano  et al., 1996). Complications of hepatitis C are mostly confined to 
patients who have developed cirrhosis. The development of cirrhosis is silent in the majority 
of patients in whom it occurs. The progression to fibrosis and later to cirrhosis depends on 
many factors, such as the duration of infection, advanced age, male sex, co-infection with 
other viruses (HIV or HBV), or alcohol intake. HCC in patients with hepatitis C occurs 
almost exclusively in those with cirrhosis, which suggests that this is the major risk factor. 
The deaths that are associated with chronic hepatitis C are more likely to be related to end-
stage liver disease rather than hepatocellular carcinoma (HCC). However, HCV accounts for 
approximately one-third of HCC cases in the United States. Estimations of the risk of 
developing HCC after the development of cirrhosis have varied from 0 to 3 percent per year 
in various reports. The risk appears to be greater with genotype 1b when compared with 
genotype 2a/c (Fattovich et al., 1997; Hu & Tong , 1999; Planas et al., 2004; Bruno  et al., 
2007).  
Once the complications of cirrhosis have occurred, liver transplantation is the only effective 
therapy. Recurrent HCV infection of the graft occurs in almost all patients, although the 
long-term survival following transplantation for HCV is similar to the survival that is 
related to other causes of hepatic failure (60 to 80 percent). Several factors may be important 
determinants of disease progression in individual patients; these factors include age, ethnic 
background, gender, HCV-specific cellular immune response, viral diversity, alcohol use, 
daily use of marijuana, viral coinfection, environmental factors and geography.  
www.intechopen.com
 
Pharmacogenomics in Gastroenterology 
 
213 
6.2 Pharmacological treatment  
The decision to treat a patient with chronic HCV infection is based upon several factors, 
which include the natural history of the disease, the stage of fibrosis, and the efficacy and 
adverse effects that are related to the therapy. For patients with clinically significant hepatic 
fibrosis, there is widespread agreement that antiviral therapy is indicated because of the 
high risk of cirrhosis. 
Currently, the standard treatment for HCV infection is ribavirin in combination with  
peg-interferon (INF), but unfortunately, approximately 50% of patients with genotype I 
do not respond to the treatment (Liapiakis & Jacobson , 2010). In contrast, 70-80%  
of patients with genotypes II or III have sustained virological response (SVR) that is 
defined as undetectable HCV RNA 6 months after the treatment. Although the treatment 
response rate depends on several factors, such as patient age, sex, viral genotype, viral 
load at the start of treatment and the liver fibrosis rate, genetic factors that may be related 
with the rate of response to treatment and disease progression have been recently 
identified (table 2). 
Ribavirin is a nucleoside analogue. The mechanism by which ribavirin contributes to its 
clinical antiviral efficacy is not fully understood. Ribavirin has direct antiviral activity in 
tissue culture against many RNA viruses. Ribavirin increases the mutational frequency in 
the genomes of several RNA viruses, and ribavirin triphosphate inhibits HCV polymerase in 
a biochemical reaction. Ribavirin is generally well tolerated. The major adverse effects 
include hemolysis, nonspecific fatigue, depression, insomnia, vertigo, anorexia, nausea, 
nasal congestion, and pruritus. As a result of hemolysis, ribavirin treatment may be 
associated with a mild reversible increase in serum bilirubin and uric acid.  
Peg-INF is derived from the recombinant human interferon Alpha2a. Alpha interferons 




 Non I HCV Genotype 
 Low viral load 
 Caucasian descent 
 IL28B Genotype 
 Absence of fibrosis 
 Weight < 85kg 
 Age< 40 years 
 Female gender 
Before treatment initiation  
 Absence of insulin resistance 
 Absence of liver steatosis 
 Use of statins 
During treatment  
 Rapid virological response (at week 4 
of treatment) 
 Adherence to treatment  
 Standard dose of ribavirin. 
Table 2. Predictors of adequate responses to treatment with ribavirin and INF in HCV  
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They induce interferon-stimulated genes (ISGs) that help to establish an antiviral status 
milieu within cells, although the response is not virus-specific. Alpha interferons act by 
binding to cell surface receptors, which activates a response cascade that culminates in the 
expression of multiple ISGs, some of which block viral protein synthesis. Peg-INF binds the 
human type I INF receptor, which leads to receptor dimerization. Receptor dimerization 
activates multiple intracellular signal transduction pathways that are initially mediated by 
the JAK/STAT signal cascade. A combination therapy with ribavirin and interferon may be 
associated with an increased risk of side effects (such as nausea, rash, and dyspnea) when 
compared to the treatment with interferon alone (table 2). However, a meta-analysis and the 
large studies that were discussed above have suggested that the incidence of serious side 
effects of these treatments are not significantly different (Schalm et al., 1997; Mc Hutchison 
et al., 1998). 
6.3 Pharmacogenomic considerations 
As aforementioned, the efficacy of INF treatment is determined by a number of factors. 
Among these factors, genetic variance has been established as an important predictor of 
treatment response and viral clearance. 
Four independent genetic studies (Genome Wide Association Study (GWAS)) have 
identified a polymorphism in the IL28B gene on chromosome 19 that encodes IFN-ʎ that has 
a strong association with the response rate to combination therapy with peg-INF and 
ribavirin (Ge et al., 2009; Suppiah et al., 2009; Tanakah et al., 2009; Rauch et al., 2010).  
Using a GWAS, several investigators from the US and the UK identified a SNP on 
chromosome 19, rs12979860. The rs12979860 SNP is 3 kb upstream of the aforementioned IL-
28B gene (Brian, 2011). Ge et al. identified rs1297960 as the variant that is most strongly 
associated with SVR in European–American, African-American and Hispanic populations. 
Their study showed an association of the CC genotype with a greater rate of SVR than the 
TT genotype. The frequency of the CC genotype was 39%, 16% and 35% in European-
American, African- American and Hispanic populations, respectively. 
Suppah et al. and Rauch et al. -in a European cohort- and Tanaka et al. -in Japanese patients- 
found the strongest association with rs8099917 (located 8 kb upstream of IL28B), which is in 
linkage disequilibrium with rs12979860. The TT genotype of rs8099917 was significantly 
associated with the presence of a sustained virological response (SVR) following treatment 
with peg-IFN and ribavirin in patients who were chronically infected with genotype 1, while 
the minor allele G is associated with the absence of the response and the increased risk of 
progression to chronic states. 
A higher prevalence of the T allele in the HIV-negative control population was also found, 
which suggests that this allele may be associated with the possibility of the clearance of the 
hepatitis C virus (Thomas et al., 2009; Aparicio et al., 2010). 
These findings may impact the prognosis and treatment of HCV infection. Furthermore, the 
ability to identify patients with a risk allele, particularly in homozygosity, in which the 
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7. Postoperative and cancer-associated nausea and vomiting 
7.1 Clinical characteristics 
Postoperative nausea and vomiting is a frequent experience for patients who are subjected 
to surgery with general anesthesia. Twenty to forty percent of surgical patients may display 
this disorder, and in certain high-risk groups, the incidence is even higher (Candiotti et al., 
2005). In addition, nausea and vomiting is one of the most distressful side effects of cytotoxic 
drugs that are administered to patients with oncologic conditions. There are multiple factors 
related to the individual risk of developing nausea and vomiting, such as female sex, young 
age, alcohol consumption, preexisting nausea, and the emetogenic potential of the 
chemotherapeutic agents that are used (Perwitasari et al., 2011).  
7.2 Pharmacological treatment 
Among the most commonly used drugs, the receptor antagonists of serotonin type 3 (5HT3), 
such as ondansetron, granisetron and tropisentron, are widely used as antiemetics to 
primarily prevent nausea and vomiting that are associated with chemotherapy and 
postoperative conditions. These drugs provide a substantial contribution toward the 
prevention and the treatment of nausea and vomiting in these scenarios. However, 20-30% 
of patients do not respond to treatment with 5HT3 antagonists.  
7.3 Pharmacogenomic considerations 
One reason that may explain these interindividual differences in the response to treatment is 
the variation in the hepatic biotransformation of the drug, which, in turn, could be 
genetically determined by polymorphic variants of the gene that encodes CYP2D6. All of the 
5HT3 antagonists are metabolized by the CYP450 complex, and they are primarily 
metabolized by the CYP2D6 isoenzyme.  
The CYP2D6 gene is mapped to chromosome 22q13.1 and encompasses nine exons with an 
open reading frame of 1383 base pairs that encode 461 amino acids (Eichelbaum et al., 1987). 
More than 63 different CYP2D6 variants have been identified by the human cytochrome 
P450 allele nomenclature. Relative to the wild type CYP2D6 allele, different variants of the 
CYP2D6 gene may result in the complete absence of enzyme activity, reduced activity, 
normal activity or even increased activity. Null alleles of CYP2D6 do not encode a functional 
protein, and there is no detectable residual enzymatic activity. These null alleles are 
responsible for the PM phenotype when they are present in homozygosity or compound 
heterozygosity. The mechanisms by which there variants are leading to a total loss of 
function include the following: a) single-base changes or small insertions/deletions that 
interrupt the reading frame or interfere with the correct splicing, which leads to a 
prematurely terminated protein or stop codon (e.g., CYP2D6*3, *4, *6, *8, *11, *15, *19, *20, 
*38, *40, *42, and *44) (Kagimoto et al., 1990); b) nonfunctional full-length coded alleles (e.g., 
CYP2D6*5, *12, *14 and *18) (Evert. et al., 1997); and c) the deletion of the entire CYP2D6 
gene as a result of large sequence deletions (e.g., CYP2D6*5, *13, and *16) (Gaedigk et al., 
1991). However, extremely high CYP2D6 activity results from the gene duplication of 
functional alleles *1 and *2 that are fused in a head-to-tail orientation as a result of unequal 
crossover events and other mechanisms. This was noted by a molecular characterization of 
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the CYP2D6 locus in patients with extremely rapid metabolism (Bertilsson et al., 1993). 
Approximately 5-10% of the Caucasian population has no activity of the enzyme (PMs) and 
approximately 2% are UMs. These patients have two active gene copies resulting in the 
production of enzymes with increased activity which will rapidly decrease the plasma 
concentration of the substrate drug with subsequent treatment failure (Lewis et al., 2010; Ho 
et al., 2006; Vermiere et al., 2010). 
Therefore, antiemetic treatment may be optimized through CYP2D6 genotyping prior to 
chemotherapy or surgical treatment by identifying the patients that will behave as PMs or 
UMs for these drugs; this analysis can specifically identify which patients would require a 
dose adjustment (Perwitasari et al., 2011). 
Because the CYP2D6 polymorphism explains only a proportion of the therapeutic failures in 
these patients, it has been postulated that changes in both the dopamine receptor and 
serotonin receptor may also be related to the antiemetic treatment response (Perwitasari, 
2011). Interestingly, it has also been postulated that CYP2D6 polymorphisms may be related 
to the predisposition to the development of dyskinesias with the use of metoclopramide, but 
the confirmation of these findings has not yet been provided (van der Padt et al., 2006). In 
summary, genetic variants may help in the individualization of drug dosing and the 
prediction of treatment outcome with the use of 5HT3 antagonists, although its routine use 
in therapeutics will require further confirmation by larger studies.  
8. Resume 
In table 3 major gastroenterological diseases are described as well as the drugs available for 

















































Type 3 serotonin receptor 
(5HT3) antagonists 
Table 3. Gastroenterological diseases, drug and associated metabolic enzyme 
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In table 4, the genes involved in the pharmacogenomic studies for gastroenterological 
diseases are summarized, as well as their effects in the enzymatic activities and phenotypic 
consequences. 
 
GENE POLIMORPHISM EFFECT CONSEQUENCES 
CYP2C19 
SNPs-Alleles: 




















Predict the occurrence of 
severe hematologic toxicity 
with irinotecan 






Impact on the prognosis and 
treatment of Hepatitis C 
with interferon 
CYP2D6 




Poor to Ultrarapid 
Metabolizers 
Table 4. The most important genes, variants and their effects on the enzymatic activities 
involved in pharmacological treatment of gastroenterological diseases. 
9. Conclusions 
In some of the most important areas of gastroenterological therapy, the relevance of 
pharmacogenomic analysis has been already demonstrated or is in the process of 
confirmation for both the identification of the proper dosage for a particular patient and the 
prevention of significant toxicity. 
The major polymorphisms (*2 and *3) of CYP2C19 associated with the phenotype of poor 
metabolizers in certain drugs, can identify patients who will achieve higher plasma 
concentrations of the main proton-pump inhibitors with the use of standard doses. Because 
this particular therapeutic group has a wide therapeutic range, the presence of higher 
concentrations is associated with higher treatment success rates for the treatment of 
Helicobacter pylori in either peptic ulcer disease or gastroesophagic reflux disease. The 
knowledge of these associations is particularly useful in populations with a higher 
prevalence of these polymorphisms. The analysis of variants in the promoter region of the 
UGT1A1 enzyme coding gene facilitates the identification of patients with Gilbert 
Meulengracht syndrome, although its pharmacogenetic relevance is currently limited to the 
cytostatic irinotecan. The experience that has been gained with the use of pharmacogenomic 
studies in the context of inflammatory bowel disease is currently limited to the analysis of 
variants of the TMPT coding gene. These variants are associated with the risk of the 
hematologic adverse effects of azathioprine, and its analysis has resulted in favourable 
pharmacoeconomic evaluations.  
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Other polymorphisms, such as the ones in the intracellular glucocorticoid receptor, the 
MDR1 gene that encodes P-glycoprotein and the TNF receptor, warrant further evaluation. 
However, to date there is no incontrovertible evidence regarding their clinical usefulness. 
The identification of polymorphisms in IL28 likely represents a potential new paradigm in 
the treatment of Hepatitis C infection. Genetic testing for antiemetic drugs will likely show 
great potential are expected to be developed in the near future, although their final 
usefulness will only be established after the acquisition of more clinical data. 
Currently, pharmacogenomics only constitutes a tool that can be utilized for personalized 
medicine, and it provides a concrete potential to predict therapeutic responses beyond the 
population level. Because it has been recently developed, it also benefits from the interest 
that is generated by its novelty. In the next few years, it will become more clear which 
aspects of this method can offer specific advantages regarding the efficacy and safety of the 
patients when compared to the aspects that are only of an academic interest.  
However, given the fact that the therapeutic experience with the use of drugs in 
gastroenterology is far from satisfactory, any firm step in the direction of individualizing 
drug treatment will facilitate better patient care. 
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